Ceregene's Drug Shows Reduction in Parkinson's Symptoms
Posted on: Thursday, 13 December 2007, 15:00 CST
Ceregene has presented positive long-term follow-up data from a Phase I clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms.
The Phase I trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites. It was previously reported that an average of 36% reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration. Of the 12 subjects treated, nine had shown a clinically meaningful reduction in symptoms at 12 months, and the mean improvement of these responders at 12 months was 46%.
The data showed that the eight evaluable responders exhibited a persistent mean improvement in symptoms of 52% at their longest time of follow-up (24 months for low-dose cohort and 18 months for high-dose cohort).
Jeffrey Ostrove, president and CEO of Ceregene, said: "We are pleased to see that the statistically significant improvement in motor symptoms seen in the Parkinson's patients 12 months after CERE-120 treatment appears to be persisting over longer time points. These positive clinical data offer further support for our recently enrolled multicenter Phase II trial for CERE-120 in the US as well as our plans to initiate another Phase II trial that will begin in the Q3 of 2008 which will be conducted in several European countries in collaboration with Genzyme."
Source: Datamonitor
Related Articles
- Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
- Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
- AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
- APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease Announces Completion of Patient Enrollment
- Alexza Completes Enrollment in AZ-004 Phase IIa Clinical Trial in Schizophrenic Patients With Acute Agitation
- Palatin Technologies and King Pharmaceuticals Complete Enrollment in Two Phase IIb Clinical Trials Evaluating Bremelanotide in Patients With Erectile Dysfunction
- Diagnostic Clinic Improves Patient Access and Saves Staff Time Through Secure Online Communications
- Inovio Biomedical and University of Southampton Collaboration: Initiation of Phase I/II Clinical Trial in Patients With Recurrent Prostate Cancer
- Cilansetron Improves Health Related Quality of Life in Multinational Phase III Clinical Trial Patients With Irritable Bowel Syndrome With Diarrhea Predominance (IBS-D)
 |
 |
User Comments (0)
RSS Feeds